Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2)

University Health Network, Toronto

Status and phase

Completed

Phase 2

Conditions

Hepatocellular Carcinoma

Treatments

Radiation: Stereotactic Body Radiation

Study type

Interventional

Funder types

Other

Identifiers

NCT00914355

UHN REB 07-0346-C

Details and patient eligibility

About

This study is designed to see whether stereotactic body radiation therapy (SBRT) can reduce tumour size, slow progression of the disease, prolong life and improve quality of life of patients with hepatocellular carcinoma, a cancer of the liver, that cannot be removed surgically (unresectable) and cannot be treated with ablative therapy (e.g. radio-frequency ablation) or trans-arterial chemo-embolization (TACE) therapy (delivery of chemotherapy through an artery that feeds into the liver). SBRT is concentrated focused radiation therapy delivered very precisely to the liver tumour. It is hoped that knowledge obtained from this study will improve our ability to treat patients with liver tumours that cannot be treated with surgery and other methods, and that SBRT may prove to be a treatment that can lead to long-term and permanent control of liver tumours for some patients.

Full description

From July 2003 to May 2007, over 40 patients with hepatocellular carcinoma participated in two studies at Princess Margaret Hospital (PMH) designed to determine the safety of treating hepatocellular carcinoma with SBRT. These studies have shown that SBRT can be delivered safely to the majority of patients with hepatocellular carcinoma. The treated tumour was controlled (shrank or remained the same size) in 78% of patients at one year following treatment.The median survival of patients was 11 months (i.e. half of patients survived longer and half shorter than 11 months). This survival rate is better than that expected in patients treated with supportive care only (no treatment other than care to make you feel better). Supportive care patients have a median survival rate of 3-9 months. We expect that the benefits of SBRT in this study will be similar to those observed in our initial studies.

Enrollment

92 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed pathologically, 2)diagnosed by showing vascular enhancement of the lesion on at least two imaging techniques, or 3) diagnosed by showing vascular enhancement on a single technique if the AFP is greater than 200, in the setting of cirrhosis or chronic hepatitis B without cirrhosis (EASL consensus conference guidelines).
Either 1) the tumour must be unresectable, based on the opinion of an experienced surgeon specializing in hepatic resection, or 2) the patient Phase II SBRT HCC 13 must be medically inoperable, or 3) extra-hepatic metastases must be present (making hepatic surgery an inappropriate treatment option).
Karnofsky performance status (KPS) > 60 (Appendix II)
Age: 18 years or older. Both male & female patients of all races can be included in this study. Female patients within reproductive years may not be, nor become, pregnant during participation in this study
Patients must have recovered from the effects of previous therapy.
Maximal tumor size of 15 cm.
Adequate organ function as assessed as follows:
- Hemoglobin > 90 g/L
- Absolute neutrophil count > 1.0 bil/L
- Platelets > 50 bil/L
- Bilirubin < 4.0 times upper range of normal
- INR < 1.5 or correctable with vitamin K (unless patient is on coumadin in which case higher levels are acceptable)
- AST or ALT < 6.0 times upper range of normal
Child's A 5-6 liver score or Child B 7-8 liver score, which is only permitted if the maximal tumor size is 10 cm
Previous liver resection or ablative therapy is permitted.
Life expectancy > 3 months
The volume of uninvolved must be at least 700 cc
Up to five discrete liver tumors
Patients must have signed a study-specific informed consent form. If the patient's mental status precludes this, written informed consent may be given by the patient's legal representative.

Exclusion criteria

Patients with active hepatitis or encephalopathy related to liver failure
Prior radiation therapy to the right upper abdomen, precluding reirradiation of the liver. That is, any previous radiation therapy in which a mean dose to the liver of 15 Gy in conventional fractionation was delivered, or previous doses to critical normal structures that would make re-irradiation unsafe. The PI should be called if there is any question of safety of re-irradiation.
Eligible for RFA or alcohol ablation
Eligible for TACE
Prior uncontrolled, life threatening malignancy within the six months.
Pregnancy is not permitted, and in women of child bearing age, a pregnancy test and acceptable methods of contraception are warranted.
Previous gastric, duodenal or variceal bleed within the past 2 months.
Commencement of coumadin use within the past 3 months.